Short answer
Regeneron Pharmaceuticals (REGN) filed its Q2 2025 10-Q quarterly report on Aug 1, 2025 for the quarter ended Jun 30, 2025. Quarterly revenue was $3.7B (up 3.6% year over year) with net income of $1.4B.
Q2 2025 key financials · XBRL
- Revenue
- $3.7B
- +3.6% YoY · +21.4% QoQ
- Net income
- $1.4B
- −2.8% YoY · +72.1% QoQ
- Operating margin
- 29.4%
- EPS (diluted)
- $12.75
- +2.7% YoY · +75.4% QoQ
Source: XBRL data from the Regeneron Pharmaceuticals (REGN) Q2 2025 10-Q on SEC EDGAR. USD.
Regeneron Pharmaceuticals Q2 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: EYLEA U.S. net product sales declined 39% YoY Q2 2025 due to intensified competition impacting near-term revenue
- Updated commercialization risk: Increased dependence on EYLEA HD as it represented 32% of aggregate EYLEA U.S. sales H1 2025 vs 44% total EYLEA sales H1 2024
- Regulatory risk: Failure to maintain or obtain marketing approvals for EYLEA or EYLEA HD could materially reduce revenue and profitability
- Operational risk: Dependence on Bayer for EYLEA commercialization outside U.S.; any disruption could materially harm global sales
- Financial risk: Concentration risk with EYLEA and EYLEA HD combined sales comprising 33% of total revenues H1 2025, exposing company to product-specific market risks
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Regeneron Pharmaceuticals quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.